[go: up one dir, main page]

TNSN98211A1 - Association d'un inhibiteur d'aldose-reductase et d'un inhibiteur de glycogene-phosphorylase, et composition pharmaceutique la contenant - Google Patents

Association d'un inhibiteur d'aldose-reductase et d'un inhibiteur de glycogene-phosphorylase, et composition pharmaceutique la contenant

Info

Publication number
TNSN98211A1
TNSN98211A1 TNTNSN98211A TNSN98211A TNSN98211A1 TN SN98211 A1 TNSN98211 A1 TN SN98211A1 TN TNSN98211 A TNTNSN98211 A TN TNSN98211A TN SN98211 A TNSN98211 A TN SN98211A TN SN98211 A1 TNSN98211 A1 TN SN98211A1
Authority
TN
Tunisia
Prior art keywords
inhibitor
glycogene
aldose
combination
pharmaceutical composition
Prior art date
Application number
TNTNSN98211A
Other languages
English (en)
Inventor
Lakshman Mylari Banavara
Hulin Bernard
Lee Treadway Judith
Jay Hoover Dennis
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of TNSN98211A1 publication Critical patent/TNSN98211A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Noise Elimination (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Superheterodyne Receivers (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

L'INVENTION CONCERNE DES ASSOCIATIONS D'INHIBITEURS D'ALDOSE - REDUCTASE ET D'INHIBITEURS DE GLYCOGENE-PHOSPHORYLASE. ELLE CONCERNE EGALEMENT DES COMPOSITIONS PHARMACEUTIQUES CONTENANT CES ASSOCIATIONS. APPLICATION : UTILISATION DE CES COMPOSITIONS POUR LE TRAITEMENT D'ETATS DE RESISTANCE A L'INSULINE TELS QUE LE DIABETE ET POUR LA REDUCTION D'UNE ALTERATION TISSULAIRE DUE A UNE ISCHEMIE.
TNTNSN98211A 1997-11-21 1998-11-18 Association d'un inhibiteur d'aldose-reductase et d'un inhibiteur de glycogene-phosphorylase, et composition pharmaceutique la contenant TNSN98211A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6636597P 1997-11-21 1997-11-21

Publications (1)

Publication Number Publication Date
TNSN98211A1 true TNSN98211A1 (fr) 2005-03-15

Family

ID=22069038

Family Applications (1)

Application Number Title Priority Date Filing Date
TNTNSN98211A TNSN98211A1 (fr) 1997-11-21 1998-11-18 Association d'un inhibiteur d'aldose-reductase et d'un inhibiteur de glycogene-phosphorylase, et composition pharmaceutique la contenant

Country Status (38)

Country Link
EP (1) EP1032424B9 (fr)
JP (1) JP2002504478A (fr)
KR (2) KR20010032304A (fr)
CN (1) CN1279617A (fr)
AP (1) AP911A (fr)
AR (1) AR016423A1 (fr)
AT (1) ATE205403T1 (fr)
AU (1) AU733304B2 (fr)
BG (1) BG104435A (fr)
BR (1) BR9814698A (fr)
CA (1) CA2310069A1 (fr)
DE (1) DE69801680T2 (fr)
DK (1) DK1032424T3 (fr)
DZ (1) DZ2656A1 (fr)
EA (1) EA002365B1 (fr)
ES (1) ES2161548T3 (fr)
GR (1) GR3037071T3 (fr)
GT (1) GT199800166A (fr)
HR (1) HRP20000327A2 (fr)
HU (1) HUP0100272A3 (fr)
ID (1) ID24524A (fr)
IL (1) IL135713A0 (fr)
IS (1) IS5453A (fr)
MA (1) MA26568A1 (fr)
NO (1) NO20002164L (fr)
OA (1) OA11379A (fr)
PA (1) PA8462301A1 (fr)
PE (1) PE135399A1 (fr)
PL (1) PL340643A1 (fr)
PT (1) PT1032424E (fr)
SK (1) SK7222000A3 (fr)
TN (1) TNSN98211A1 (fr)
TR (1) TR200001451T2 (fr)
UA (1) UA57811C2 (fr)
UY (1) UY25258A1 (fr)
WO (1) WO1999026659A1 (fr)
YU (1) YU30700A (fr)
ZA (1) ZA9810636B (fr)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2535700A (en) * 1999-02-12 2000-08-29 Novo Nordisk A/S Use of pyrrolidine derivatives for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of obesity or appetite regulation
DE60132723T2 (de) 2000-01-21 2009-01-29 Novartis Pharma Ag Zusammensetzungen bestehend aus Dipeptidylpeptidase-IV Inhibitoren und Antidiabetica
CO5271699A1 (es) 2000-01-24 2003-04-30 Pfizer Prod Inc Procedimiento para el tratamiento de cardiomiopatia utilizando inhibidores de la glucogeno fosforilasa
US6570013B2 (en) 2000-02-16 2003-05-27 Pfizer Inc Salts of zopolrestat
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
IL144507A0 (en) * 2000-07-31 2002-05-23 Pfizer Prod Inc Use of glycogen phosphorylase inhibitors to inhibit tumor growth
WO2002098429A1 (fr) * 2001-06-07 2002-12-12 Pfizer Products Inc. Formes salines du zopolrestat, a savoir ethanolamine, diethanolamine ou triethanolamine
GB0205162D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205165D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205166D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205176D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205170D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205175D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
US7057046B2 (en) 2002-05-20 2006-06-06 Bristol-Myers Squibb Company Lactam glycogen phosphorylase inhibitors and method of use
CA2392486A1 (fr) 2002-07-05 2002-12-08 Duchesnay Inc. Forme posologique pharmaceutique portant une inscription pour les femmes enceintes
US7098235B2 (en) 2002-11-14 2006-08-29 Bristol-Myers Squibb Co. Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds
US7767828B2 (en) 2003-11-12 2010-08-03 Phenomix Corporation Methyl and ethyl substituted pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
NZ547752A (en) 2003-11-12 2009-12-24 Phenomix Corp Heterocyclic boronic acid compounds for inhibiting dipeptidyl peptidase-IV
US7576121B2 (en) 2003-11-12 2009-08-18 Phenomix Corporation Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
US7317109B2 (en) 2003-11-12 2008-01-08 Phenomix Corporation Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
WO2006017292A1 (fr) 2004-07-12 2006-02-16 Phenomix Corporation Composes cyano contraints
WO2006055463A2 (fr) 2004-11-15 2006-05-26 Bristol-Myers Squibb Company Derives de 2-amino-3-tetraline fonctionnalisee et inhibiteurs de la glycogene phosphorylase associes
WO2006053274A2 (fr) 2004-11-15 2006-05-18 Bristol-Myers Squibb Company Derives de tetraline 2-amino-1-fonctionnalises et inhibiteurs correspondants de glycogene phosphorylase
US7226942B2 (en) 2004-11-15 2007-06-05 Bristol-Myers Squibb Company 2-amino-4-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
US7223786B2 (en) 2004-11-15 2007-05-29 Bristol-Myers Squibb Company 2-aminonaphthalene derivatives and related glycogen phosphorylase inhibitors
WO2006113261A2 (fr) 2005-04-14 2006-10-26 Bristol-Myers Squibb Company Inhibiteurs de la 11-beta hydroxysteroide deshydrogenase de type i
US7825139B2 (en) 2005-05-25 2010-11-02 Forest Laboratories Holdings Limited (BM) Compounds and methods for selective inhibition of dipeptidyl peptidase-IV
GEP20135791B (en) 2005-09-14 2013-03-25 Takeda Pharmaceutical Use of dipeptidyl peptidase inhibitors
WO2008005910A2 (fr) 2006-07-06 2008-01-10 Bristol-Myers Squibb Company Inhibiteurs de type i de la 11-bêta hydroxystéroïde déshydrogénase pyridone/hydroxypyridine
US7727978B2 (en) 2006-08-24 2010-06-01 Bristol-Myers Squibb Company Cyclic 11-beta hydroxysteroid dehydrogenase type I inhibitors
US8546394B2 (en) 2007-04-17 2013-10-01 Bristol-Myers Squibb Company Substituted [1,2,4]triazolo[4,3-A]pyrazine 11-beta-hydroxysteroid dehydrogenase inhibitors
JP2010526145A (ja) 2007-05-04 2010-07-29 ブリストル−マイヤーズ スクイブ カンパニー ［６，６］および［６，７］−二環式ｇｐｒ１１９ｇタンパク質結合受容体アゴニスト
US8093257B2 (en) 2007-05-04 2012-01-10 Bristol-Myers Squibb Company [6,5]-bicyclic GPR119 G protein-coupled receptor agonists
NZ582661A (en) 2007-07-17 2012-03-30 Bristol Myers Squibb Co Method for modulating gpr119 g protein-coupled receptor and selected compounds
TW201006821A (en) 2008-07-16 2010-02-16 Bristol Myers Squibb Co Pyridone and pyridazone analogues as GPR119 modulators
WO2011041293A1 (fr) 2009-09-30 2011-04-07 Takeda Pharmaceutical Company Limited Dérivés pyrazolo [1, 5—a] pyrimidines comme inhibiteurs de kinase 1 régulatrice de signal d'apoptose
US8802695B2 (en) 2010-02-03 2014-08-12 Takeda Pharmaceutical Company Limited Apoptosis signal-regulating kinase 1 inhibitors
SG184168A1 (en) 2010-04-08 2012-10-30 Bristol Myers Squibb Co Pyrimidinylpiperidinyloxypyridinone analogues as gpr119 modulators
US8592396B2 (en) 2010-04-14 2013-11-26 Bristol-Myers Squibb Company Glucokinase activators and methods of using same
JP2013525489A (ja) 2010-05-06 2013-06-20 ブリストル−マイヤーズ スクイブ カンパニー Ｇｐｒ１１９修飾因子としての二環式ヘテロアリール類似体
US8729084B2 (en) 2010-05-06 2014-05-20 Bristol-Myers Squibb Company Benzofuranyl analogues as GPR119 modulators
US9566269B2 (en) 2011-01-20 2017-02-14 Bionevia Pharmaceuticals Inc. Modified release compositions of epalrestat or a derivative thereof and methods for using the same
US9174965B2 (en) 2012-05-16 2015-11-03 Bristol-Myers Squibb Company Pyrimidinylpiperidinyloxypyridone analogues as GPR119 modulators
US9580422B2 (en) 2013-10-22 2017-02-28 Bristol-Myers Squibb Company Isotopically labeled triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
WO2018017910A1 (fr) 2016-07-22 2018-01-25 Bristol-Myers Squibb Company Activateurs de glucokinase et leurs procédés d'utilisation

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4825448A (en) * 1986-08-07 1989-04-25 International Mobile Machines Corporation Subscriber unit for wireless digital telephone system
DE3889326D1 (de) * 1988-05-27 1994-06-01 Itt Ind Gmbh Deutsche Korrekturschaltung für ein digitales Quadratur-Signalpaar.
US5391551A (en) * 1993-05-10 1995-02-21 Pfizer Inc. Method of lowering blood lipid levels
FI974437A0 (fi) * 1995-06-06 1997-12-05 Pfizer Substituoituja N-(indoli-2-karbonyyli)amideja ja johdannaisia glykogeenifosforylaasi-inhibiittoreina
MX9709875A (es) * 1995-06-06 1998-03-31 Pfizer N-(indol-2-carbonil)-glicinamidas substituidas y derivados como inhibidores de glicogeno fosforilasa, composiciones que las contienen y uso de las mismas.

Also Published As

Publication number Publication date
HRP20000327A2 (en) 2001-02-28
SK7222000A3 (en) 2001-09-11
ZA9810636B (en) 2000-05-22
PL340643A1 (en) 2001-02-12
BR9814698A (pt) 2000-10-03
KR100661214B1 (ko) 2006-12-26
PT1032424E (pt) 2001-12-28
EP1032424B1 (fr) 2001-09-12
YU30700A (sh) 2002-12-10
ATE205403T1 (de) 2001-09-15
PA8462301A1 (es) 2000-05-24
DE69801680T2 (de) 2002-02-07
EP1032424B9 (fr) 2004-10-06
EA200000433A1 (ru) 2000-12-25
EA002365B1 (ru) 2002-04-25
JP2002504478A (ja) 2002-02-12
IS5453A (is) 2000-04-14
ID24524A (id) 2000-07-20
CA2310069A1 (fr) 1999-06-03
WO1999026659A1 (fr) 1999-06-03
GT199800166A (es) 2000-04-19
GR3037071T3 (en) 2002-01-31
PE135399A1 (es) 2000-01-15
EP1032424A1 (fr) 2000-09-06
NO20002164L (no) 2000-07-19
UY25258A1 (es) 2000-12-29
UA57811C2 (uk) 2003-07-15
HUP0100272A2 (hu) 2001-06-28
BG104435A (bg) 2001-01-31
CN1279617A (zh) 2001-01-10
IL135713A0 (en) 2001-05-20
DK1032424T3 (da) 2001-11-19
MA26568A1 (fr) 2004-12-20
ES2161548T3 (es) 2001-12-01
AP911A (en) 2000-12-07
AU9555898A (en) 1999-06-15
TR200001451T2 (tr) 2002-06-21
AP9801401A0 (en) 1998-12-31
NO20002164D0 (no) 2000-04-27
AU733304B2 (en) 2001-05-10
HUP0100272A3 (en) 2002-11-28
OA11379A (en) 2004-01-28
KR20010032300A (ko) 2001-04-16
AR016423A1 (es) 2001-07-04
KR20010032304A (ko) 2001-04-16
DE69801680D1 (de) 2001-10-18
DZ2656A1 (fr) 2003-03-22

Similar Documents

Publication Publication Date Title
TNSN98211A1 (fr) Association d'un inhibiteur d'aldose-reductase et d'un inhibiteur de glycogene-phosphorylase, et composition pharmaceutique la contenant
TNSN96085A1 (fr) Amides therapeutiques et compositions les contenant
TNSN98017A1 (fr) Derives de sulfonyluree, procede pour leur preparation et compositions pharmaceutiques les contenant.
TNSN97208A1 (fr) Prevention de la perte et restauration de la masse osseuse par certains agonistes des prostaglandines
EP1385508A4 (fr) Inhibiteurs de peptidase dipeptidyl destines au traitement ou a la prevention du diabete
TNSN99172A1 (fr) 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinoleines, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN96104A1 (fr) Trihydrate de metahensulfonate de (1s,2s)-1-(4-hydroxyphenyl) -2-(4-hydroxy-4-phenylpiperidine-1-yl)-1-propanol et composition pharmaceutique le contenant
TNSN01170A1 (fr) Associations d'agonistes de gaba et d'inhibiteurs d'aldose-reductase.
MA24729A1 (fr) Macrolides nouveaux.
BR9806060A (pt) Composto, composição farmacêutica e processos para tratar um paciente sofrendo de um estado doentio, para inibir o fator xa, e, para inibir a formação de trombina.
TNSN98084A1 (fr) Derives de macrolides substitues en position c-4
TNSN99171A1 (fr) 4-carboxyamino-2-substitue-1,2,3,4-tetrahydroquinoleines, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN99006A1 (fr) 4-(2-ceto-1-benzimidazolinyl) piperidines nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
BR9810984A (pt) Composto de triazol, uso do mesmo, e, composição farmacêutica
BR9909358A (pt) Composto, composição farmacêutica, e, processo para prevenção ou alìvio de complicações crÈnicas decorrentes de diabetes melito
CA2222303A1 (fr) Utilisation d'au moins un inhibiteur de no-synthase dans le traitement des peaux sensibles
NL300175I2 (nl) Methylsulfonylfenyl-2-(5H)-furanonen als remmers van COX-2.
MA27556A1 (fr) Derives de phenylalanine comme inhibiteurs de la dipeptidyl peptidase pour le traitement ou la prevention du diabete
TNSN01119A1 (fr) Compositions contenant des inhibiteurs de la proteine de transfert d'ester de cholesteryle
BR9814327A (pt) Compostos de tiouréia e benzamida, composições e pro-cessos para tratamento ou prevenção de doenças infla-matórias e arteriosclerose
PE44895A1 (es) Compuesto derivado de benzotiofeno que puede inhibir la perdida osea y disminuir el colesterol en suero
TNSN97139A1 (fr) Derives d'acides d'arylsulfonylaminohydroxamiques
TNSN02014A1 (fr) Composes nouveaux agonistes de ppar et compositions les contenant
TNSN99055A1 (fr) Derives bicycliques d'acide hydroxamique nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
ES2131185T3 (es) Arilalcanil-n-hidroxiureas y heteroalquilalcanil-n-hidroxiureas sustituidas que pueden inhibir la biosintesis de leucotrienos.